Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis

Jin-Hang Gao1,2,*, Shi-Lei Wen1,3,*, Wen-Juan Yang2, Yao-Yao Lu2, Huan Tong2, Zhi-Yin Huang2, Zhang-Xu Liu4, Cheng-Wei Tang1,2#

1 Division of Peptides Related with Human Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, 2 Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China, 3 Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China, 4 Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America

Abstract

Background: Increased intra-hepatic resistance to portal blood flow is the primary factor leading to portal hypertension in cirrhosis. Up-regulated expression of cyclooxygenase-2 (COX-2) in the cirrhotic liver might be a potential target to ameliorate portal hypertension.

Objective: To verify the effect of celecoxib, a selective inhibitor of COX-2, on portal hypertension and the mechanisms behind it.

Methods: Cirrhotic liver model of rat was established by peritoneal injection of thiacetamide (TAA). 36 rats were randomly assigned to control, TAA and TAA+celecoxib groups. Portal pressures were measured by introduction of catheters into portal vein. Hepatic fibrosis was assessed by the visible hepatic fibrotic areas and mRNAs for collagen III and α-SMA. The neovascularization was determined by hepatic vascular areas, vascular casts and CD31 expression. Expressions of COX-2, vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2) and related signal molecules were quantitated.

Results: Compared with TAA group, the portal pressure in TAA+celecoxib group was significantly decreased by 17.8%, p<0.01. Celecoxib treatment greatly reduced the tortuous hepatic portal venules. The data of fibrotic areas, CD31 expression, mRNA levels of α-SMA and collagen III in TAA+celecoxib group were much lower than those in TAA group, p<0.01. Furthermore, the up-regulation of hepatic mRNA and protein levels of VEGF, VEGFR-2 and COX-2 induced by TAA was significantly inhibited after celecoxib treatment. The expressions of prostaglandin E2 (PGE2), phosphorylated extracellular signal-regulated kinase (p-ERK), hypoxia-inducible factor-1α (HIF-1α), and c-fos were also down-regulated after celecoxib treatment.

Conclusions: Long term administration of celecoxib can efficiently ameliorate portal hypertension in TAA rat model by its dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. The anti-angiogenesis effect afforded by celecoxib may attribute to its modulation on VEGF/VEGFR-2 through the down-regulation of integrated signal pathways involving PGE2-HIF-1α-VEGF and p-ERK- c-fos- VEGFR-2.

Citation: Gao J-H, Wen S-L, Yang W-J, Lu Y-Y, Tong H, et al. (2013) Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis. PLoS ONE 8(7): e69309. doi:10.1371/journal.pone.0069309

Editor: Ashraf B. Abdel-Naim, Faculty of Pharmacy, Ain Shams University, Egypt

Received February 16, 2013; Accepted June 12, 2013; Published July 26, 2013

Copyright: © 2013 Gao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study is supported by Grant #81170413 of Natural Science Fund of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: shqcdmed@163.com

# These authors contributed equally to this work.

Introduction

Portal hypertension, a major complication of advanced liver cirrhosis [1], is the result of increased vascular resistance in the portal circulation, increased portal venous blood flow, or both. Its life-threatening consequences carry a poor prognosis and represent the first cause of death and need for liver transplantation in patients with cirrhosis [2]. Unfortunately, the efficacy of pharmacological therapy aimed at correcting the increased splanchnic blood flow is limited to control portal hypertension.

Fibrosis, regenerative nodule formation, and intrahepatic vasoconstriction are classical mechanisms that account for increased intrahepatic vascular resistance in cirrhosis. Recent data suggest that intrahepatic angiogenesis could also be involved in fibrosis and portal hypertension [2,3]. Liver cirrhosis is closely associated with increased angiogenesis, and the neovascularization is mainly located in the fibrotic areas of the liver [4–6]. Angiogenesis refers to the development of new blood vessels from the existing vasculature [7]. In support of this, vascular endothelial growth...
factor (VEGF), placental growth factor and angiopoietin I have been found to be over expressed in cirrhotic liver [5,8–10]. Anti-angiogenesis strategy has recently emerged as an actively investigated treatment for liver cirrhosis [11]. Several angiogenesis inhibitors, such as bevacizumab, sorafenib, sunitinib, pazopanib and everolimus, have been approved or tested in the treatment of hepatocellular carcinoma [12] but not for the application in the patients with liver cirrhosis because of their toxicities and side effects [13,14].

Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme involved in the conversion of arachidonic acid to prostaglandins (PGs) and thromboxanes [15]. COX-2 expression is up-regulated in the cirrhotic liver [16]. COX-2 inhibitors can reduce angiogenesis in hepatocellular carcinoma and other tumors [17–20]. However, the effect of selective COX-2 inhibitors on the angiogenesis in cirrhotic liver remains unclear. Celecoxib, a selective COX-2 inhibitor, is safe and has been widely applied in the treatment of rheumatic diseases. In this study, we investigated the antiangiogenic and antifibrotic effects of celecoxib on the development of liver cirrhosis in rats treated with thiacetamide (TAA).

Materials and Methods

Animal Care

All the rats used in this study were kept under a 12 h light-dark cycles at a constant temperature and humidity with free access to chow and water. The animal procedures were approved by the Animal Use and Care Committee of Sichuan University and were conducted according to the regulations set by Sichuan University.

Animals and Experimental Designs

Peritoneal injection (i.p.) of TAA (Sigma Chemical Co., St. Louis, MO, USA) was employed to induce liver cirrhosis (200 mg/ kg every 3 days for 16 weeks). 36 male Sprague-Dawley rats (Experimental Animal Center of Sichuan University, Chengdu, China), weighing 180 to 230 g, were randomized into control, TAA and TAA+celecoxib groups with 12 animals in each group. TAA+celecoxib group received TAA plus celecoxib (20 mg/kg/day, Pfizer, New York, NY, USA) by gastric gavage from the initiation of TAA administration. TAA group received TAA plus placebo and control group received injections of normal saline (1mL i.p., every 3 days). The rats in each group were sacrificed under anesthesia at the end of experiments. Portions of liver tissues were fixed in 4% neutral buffered paraformaldehyde for histopathologic and immunohistochemical examinations, or immediately frozen in liquid nitrogen and stored at −80 °C for further RNA and protein analysis. Serum was collected and stored at −80 °C until analysis.

Histopathological Study of Liver Cirrhosis and Angiogenesis

Liver tissues fixed in 4% paraformaldehyde were embedded in paraffin, sectioned (thickness of 6 μm), and then stained with hematoxylin and eosin (HE) and Masson trichrome (MT). The morphological changes were examined under a microscope (CX41, Olympos, Tokyo, Japan) equipped with a digital camera (DP72, Olympos, Tokyo, Japan) and analyzed by Image-Pro Plus 4.0 software (Media Cybernetics, Silver Spring, MD, USA). The vascular areas were measured on HE staining sections at ×100 magnifications. The percentages of fibrotic areas were calculated for each MT-stained section at ×100 magnifications. To avoid the sampling bias in the semi-quantitative analysis, a total of 12 pieces of liver tissues from each animal were obtained (3 pieces from each of the left lateral, right medial and right lateral lobes; 1 piece from each of the other 3 small lobes).

Vascular Corrosion Casting and Scanning Electron Microscope (SEM) of Liver Vasculature

Liver vascular corrosion casts, which explore the three dimensional morphology of the hepatic microcirculation, were performed in three rats from each group. The rats were deeply anesthetized with chloral hydrate. The livers were first perfused with heparin saline solution (contains 500 U/mL of heparin) through a cannula placed in the portal vein. After that, the vasculature of the rat livers were perfused in situ via the portal vein with a freshly prepared solution of methyl methacrylate (Sigma Chemical Co., St. Louis, MO, USA) containing 0.2 g of benzoyl peroxide (Sigma Chemical Co., St. Louis, MO, USA) per 100 mL of resin. After perfusion, the livers were excised and placed in a water bath for 72 hours to complete the polymerization of the perfused resin, and then the livers were immersed in 15% potassium hydroxide to digest the tissue off the cast, which was usually achieved in 4 to 5 weeks. The vascular casts were washed in running water and air-dried. Finally, the liver vascular corrosion casts were coated with gold and examined by SEM (JSM-7500F, JEOL, Japan).

Immunohistochemical Studies for Liver Sections

Liver tissues were processed for paraform embedding and 3 μm sections. The sections were deparaffinized in xylen and serial ethanol dilutions. Antigen retrieval was performed by heating the sections in 10 mM sodium citrate buffer. Sections were blocked and incubated with primer antibody overnight at 4 °C and developed with biotinylated secondary antibodies and then incubated with streptavidin–biotin-complex. The sections were then stained with a solution of 3, 3-diaminobenzidine tetrahydrochloride and counterstained with haematoxylin. The positive areas of VEGF (1:100, Abcam, Cambridge, UK), COX-2 (1:150, Santa Cruz Biotechnology, Santa Cruz, CA, USA), phosphorylated extracellular signal-regulated kinase (p-ERK, 1:100, Signalway Antibody, Pearland, TX, USA) and VEGF receptor 2 (VEGFR-2, 1:100, Bioss, Beijing, China) were quantified by using Image-Pro Plus 4.0 software to score integrated optical density (IOD) at ×400 magnifications. For the quantification of sections stained for CD31 (1:200, Bioss, Beijing, China), five random fields at ×400 magnifications were captured and the percentages of CD31-positive areas were calculated for each liver section.

Western Blot Analysis for Hepatic Protein Expression

Proteins were extracted from the livers using a protein extraction kit (Nanjing Kaji, Nanjing, China) following guidelines from the manufacturer. 100 μg of proteins were electrophoresed on 10% SDS-PAGE. The gels were then blotted onto a nitrocellulose membrane (Millipore, Bedford, MA, USA). Non-specific binding sites in the membranes were blocked with 5% non-fat dry milk in incubation buffer before addition of antibodies against rat VEGF (1:500), VEGFR-2 (1:1000), CD31 (1:200), COX-2 (1:400) and β-actin (1:200, Bioss, Beijing, China). The blots were washed and incubated for one hour at room temperature with appropriate HRP-conjugated secondary antibodies. Protein bands were visualized by using an ECL detection kit (Amersham Pharmacia, Uppsala, Sweden). The autoradiographs were scanned after exposing the membranes to Kodak XAR film (Eastman Kodak, Rochester, NY, USA). Protein expression was determined by using Quantity One software.
Quantitative Real-time PCR (qRT-PCR) for Hepatic mRNA Expression

Total RNA was extracted from rat liver tissues by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). 5 μg of RNA was reverse-transcribed using a first-strand cDNA kit with random hexamers (Fermentas, Burlington, Canada) and qRT-PCR performed by using the SooFast EvaGreen PCR master mix (Bio-Rad, Hercules, CA, USA). Intron-spanning primers are listed in Table 1. All reactions were run in duplicate by using a CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA, USA). The mRNA expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by using the 2^(-ΔΔCt) method and shown as fold changes.

Enzyme-Linked Immunosorbent Assay (ELISA) for Serum Prostaglandin E2 (PGE2)

The concentration of serum PGE2 was quantified with an ELISA kit according to the manufacturer’s instructions (USCN Life Sciences Inc, Wuhan, China). Plates were read using the Thermo microplate reader (Thermo Fisher scientific, San Jose, CA, USA) under the wavelengths of 450 nm.

Hemodynamic Studies of Portal Pressure and Mean Artery Pressure

At the end of respective treatments, hemodynamic measurements were performed under chloral hydrate anaesthesia. PE-50 catheters were introduced into the carotid artery and portal vein separately to measure mean arterial pressure, heart rate and portal pressure. The measurements were recorded on a multichannel computer-based recorder BL420 (Taimeng Technology Co., Chengdu, China).

Serum Biochemistry for Liver and Renal Function Parameters

The serum was collected and analyzed for liver and renal function parameters by an Olympus AU2700 analyser (Olympus, Tokyo, Japan), according to standard tests based on the recommendations of the International Federation of Clinical Chemistry.

| Gene   | GenBank Accession No. | Forward sequence (5’-3’)        | Reverse sequence (5’-3’)       | Expected Product Size |
|--------|-----------------------|---------------------------------|--------------------------------|-----------------------|
| GAPDH  | NM_017008             | TCGGTGTGACGAGGATTGG             | CTCAGCCTTGACGTGGCC             | 173 bp                |
| CD31   | NM_031591             | CTTCACATCCAGAACAGAAGGAGAC       | CATGTTTCTCAGAGTGGTT            | 360 bp                |
| COX-2  | NM_017232             | GCTCATCTAGAGGAGAGAGGCA          | TGGAACTGCTGTTGAAAG             | 117 bp                |
| VEGF   | NM_031836             | CGAAGCTTCCGAGAGACGC             | GACGCGAGCAGTGTG              | 139 bp                |
| VEGF-R2| NM_013062             | CATAATAGAAGGCCTCAGGG            | GCTCATCCAGGCGAGT              | 191 bp                |
| HIF-1α | NM_024359             | TCCGGGAGCTGACGAC                | CAGAGGAGCATGAGAAG              | 130 bp                |
| e-foS  | NM_022197             | ACCACCAAGGACCTTGGG             | CGACCTGGACGATGAG              | 142 bp                |
| Collagen III | NM_032085 | GAGTGGGTCCTACAAACAACACT | CACCTGGCTGTTGAGGA  | 241 bp                |
| α-SMA  | NM_031004             | CGGAGATCCACGGACTACC             | TCCAGGGACATAGGAC              | 120 bp                |

HIF-1α, Hypoxia-inducible factor-1α; α-SMA, alpha-smooth muscle actin.
doi:10.1371/journal.pone.0069309.t001

Statistical Analysis

All data were expressed as mean ± SD and analyzed by SPSS 13.0 software (SPSS, Chicago, IL, USA). One-way ANOVA test was applied in the comparisons among three groups. Then, a stepwise multiple comparisons procedure, Student-Newman-Keuls test was used to identify sample means that were significantly different from each other. A value of p<0.05 was considered significant.

Results

Successful Cirrhotic Liver Model Induced by TAA Treatment

Compared with the livers in control group, a typical cirrhotic appearance with extensive nodular formation was presented in the livers of rats treated with TAA for 16 weeks. Little or mild intrahepatic inflammatory infiltration was detected in these cirrhotic rats. MT staining sections (Figure 1) further revealed the fibrotic nodules and the distortion of hepatic structure in the rat livers of TAA group. The fibrotic area of liver tissues in TAA group were dramatically increased by 25 folds when compared with that of control group, p<0.01. Moreover, hepatic mRNAs for collagen III and alpha smooth muscle actin (α-SMA) in TAA model were 5.3 and 2.5 folds higher than those in control group, p<0.01.

One rat died in each of the TAA and TAA+celecoxib group while no death was observed in control group. No significant differences in the serum levels of ALT, AST, total protein, albumin, bilirubin, urea and creatinine were observed among the three groups, p>0.05 (Table 2).

Reduction of Hepatic Fibrosis with Celecoxib Treatment

The hepatic nodules induced by TAA were almost not observed in TAA+celecoxib group (Figure 1, upper panel). The hepatic histopathological lesions were also substantially reduced in TAA+celecoxib group. In support of this, the fibrotic areas of liver tissues in TAA+celecoxib group were significantly decreased by 49% when compared with TAA group (10.6±0.9% vs. 20.8±1.5%, p<0.01). The up-regulated mRNAs for collagen III and α-SMA with TAA treatment were also greatly decreased with the addition of celecoxib (Figure 1).

Table 1. List of primers for qRT-PCR.
Inhibition of Hepatic Neangiogenesis with Celecoxib Treatment

Tissue sections stained with HE and MT revealed that hepatic vascular areas in TAA group were greatly enlarged when compared with those in control group (0.0325 ± 0.0086 mm² vs. 0.1502 ± 0.0143 mm², \( p < 0.01 \)) (Figure 2). Such findings were further confirmed by the three-dimensional changes of portal veins. Vascular casts showed much more irregular, tortuous portal veins in the livers of TAA group. Correspondingly, the up-expression of hepatic CD31 in TAA group was visualized by immunohistochemistry. Furthermore, mRNA and protein levels of CD31 in TAA group were over one fold higher than those in control group, \( p < 0.01 \) (Figure 2).

Interestingly, beside the vascular areas in TAA + celecoxib group were greatly reduced (0.1502 ± 0.0143 mm² vs. 0.0485 ± 0.0097 mm², \( p < 0.01 \)) (Figure 2). Such findings were further confirmed by the three-dimensional changes of portal veins. Vascular casts showed much more irregular, tortuous portal veins in the livers of TAA group. Correspondingly, the up-expression of hepatic CD31 in TAA group was visualized by immunohistochemistry. Furthermore, mRNA and protein levels of CD31 in TAA group were over one fold higher than those in control group, \( p < 0.01 \) (Figure 2).

### Table 2. Effects of celecoxib on the liver and renal functions.

|                | Control  | TAA       | TAA+Celecoxib |
|----------------|----------|-----------|---------------|
| ALT (IU/L)     | 67.9 ± 15.6 | 78.2 ± 8.1 | 82.0 ± 17.6   |
| AST (IU/L)     | 196.4 ± 25.4 | 215.2 ± 34.0 | 220.7 ± 28.6 |
| Total protein (g/L) | 53.9 ± 4.8 | 53.3 ± 3.1 | 53.5 ± 3.1 |
| Albumin (g/L)  | 34.5 ± 3.6 | 31.5 ± 2.7 | 34.5 ± 2.7 |
| Bilirubin (μmol/L) | 1.5 ± 0.6 | 1.4 ± 0.6 | 1.7 ± 1.0 |
| Urea (mmol/L)  | 8.07 ± 1.68 | 8.92 ± 2.61 | 7.80 ± 1.59 |
| Creatinine (μmol/L) | 55.5 ± 16.5 | 45.6 ± 11.7 | 52.0 ± 12.7 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

DOI:10.1371/journal.pone.0069309.t002

Suppression of Angiogenesis through the Integrated Signal Pathways with Celecoxib Treatment

Immunohistochemical staining showed that the up-expressions of VEGF and VEGFR-2 in the liver of TAA group were markedly decreased with the addition of celecoxib (Figure 3). Consistently, the mRNA and protein quantifications of hepatic VEGF and VEGFR-2 in TAA group were increased over one-fold when
compared with those in control group, but were significantly reduced with the celecoxib treatment (Figure 3).

The hepatic mRNA for COX-2 in TAA group was the highest among three groups \( (p<0.01) \). The up-regulation of COX-2 protein in TAA group was either shown by immunohistochemical staining or measured by Western blot when compared with control group. With the addition of celecoxib, the hepatic COX-2 protein was dramatically down-regulated (Figure 4, \( p<0.01 \)).

As the product of COX-2 protein, the serum concentration of PGE2 in TAA group was also the highest among three groups \( (p<0.01) \). Consequently, the mRNA expression of hepatic hypoxia-inducible factor-1\( \alpha \) (HIF-1\( \alpha \)), one of the downstream molecules of PGE2 and stimulator of VEGF, was significantly
increased in TAA group when compared with that in control group, but was greatly decreased by the celecoxib treatment, \( p < 0.01 \) (Figure 4). In addition, hepatic p-ERK/c-fos pathway, a link between ERK and VEGF, was greatly activated in TAA model \( (p < 0.01) \), but was suppressed by the addition of celecoxib \( (p < 0.01) \).

**Increase of Portal Hypertension by Celecoxib Treatment**

There were no significant differences of the mean arterial pressure and heart rate among three groups, \( p > 0.05 \) (Figure 5). However, the portal pressure in TAA group was significantly increased by 60.7\% \( (14.88 \pm 0.84 \text{ mmHg vs. } 9.26 \pm 1.39 \text{ mmHg, } p < 0.01) \) when compared with that in control group. It is valuable that the portal pressure in TAA+celecoxib group was significantly decreased by 17.8\% \( (14.88 \pm 0.84 \text{ mmHg vs. } 12.23 \pm 1.09 \text{ mmHg, } p < 0.01) \) (Figure 5).

**Discussion**

Over the past two decades, significant advances in understanding of the molecular and cellular mechanisms underlying the development of liver cirrhosis have been achieved. It is generally accepted that activation of hepatic stellate cells (HSCs) and deposition of extracellular matrix are the driving forces leading to liver fibrosis and cirrhosis [21]. However, to date, many specific

![Figure 3. Suppression of angiogenetic factors by celecoxib treatment. Much more positive expressions for VEGF and VEGFR-2 were visualized in TAA group (1st - 2nd panels, Immunohistochemical stain, \( \times 400 \) magnifications; inserts, \( \times 1000 \) magnifications). The mRNA and protein levels of hepatic VEGF and VEGFR-2 in TAA group measured with qRT-PCR and Western blot respectively were the highest among three groups. \# \( p < 0.01 \) vs. control group; * \( p < 0.01 \) vs. TAA group. doi:10.1371/journal.pone.0069309.g003](https://www.plosone.org/article/static/0069309/g003)
anti-fibrotic treatments have been tried, including inhibition of collagen synthesis, interruption of matrix deposition, stimulation of matrix degradation, modulation of HSCs activation, or induction of HSCs death, but none has succeeded yet [22,23]. The cirrhotic liver model induced by TAA treatment in this study showed up-regulation of COX-2. By sufficiently inhibiting it for 16 weeks, celecoxib at the routinely recommended dosage effectively reduced visible hepatic fibrotic area and down-regulated hepatic mRNAs for collagen III and α-SMA. The mechanism underlying the anti-fibrogenic effect of celecoxib may be considered as induction of HSCs apoptosis through inhibition of Akt activation [24].

Liver cirrhosis is inevitable ultimate outcome triggered by consistent chronic liver injury and inflammation. Chronic inflammation is usually accompanied by angiogenesis [8]. Angiogenesis is a dynamic process leading to the formation of new vessels from pre-existing blood vessels, by sprouting or intussusception, then lumen formation and eventually stabilization of nascent vessels [25]. Recently, there is growing evidences supporting a causative role for angiogenesis in the development of fibrosis and portal hypertension in animal models [3,10]. The results from this study also suggested that angiogenesis directly correlated with the degree of hepatic fibrosis. Indeed, intrahepatic angiogenesis and fibrosis developed in parallel in the TAA rat model. Several studies have administered anti-angiogenic drugs in

Figure 4. Suppression of the integrated signal pathways with celecoxib treatment. Much more positive expressions for COX-2 and p-ERK were visualized in TAA group (Immunohistochemical stain, ×400 magnifications; inserts, ×1000 magnifications). The mRNA and protein levels of hepatic COX-2 in TAA group measured with qRT-PCR and Western blot separately were the highest among three groups. The serum levels of PGE2 were measured by ELISA. The mRNAs for HIF-1α and c-fos were determined by qRT-PCR. # p<0.01 vs. control group; * p<0.01 vs. TAA group. doi:10.1371/journal.pone.0069309.g004
animal models of cirrhosis with the aim of decreasing liver fibrosis and portal hypertension. The effect and benefit of anti-angiogenic interventions on the development of liver cirrhosis remain still controversial in the experimental models [26,27]. Similar to anti-angiogenesis in hepatocellular carcinoma [17–20], this study showed an obvious inhibitory effect of celecoxib on the angiogenesis in the cirrhotic livers induced by TAA in terms of the reduced hepatic vascular areas, less tortuous portal veins displayed by vascular casts, and down-expression of hepatic CD31.

Of the numerous angiogenic factors discovered thus far, VEGF has been identified as a key mediator of neoangiogenesis. Elevated expression of VEGF in the cirrhotic livers of this study further indicated that liver cirrhosis is accompanied by angiogenesis and it is rational to suppress intrahepatic VEGF expression. Similar to sorafenib, which down-regulated the activity and expression of VEGF and VEGFR2 in mesenteries [26], celecoxib significantly reduced intrahepatic VEGF and VEGFR-2 by 37% and 62%, respectively. Among the integrated signal pathways linking COX-2 and VEGF, both PGE2 produced by COX-2 and its downstream molecular, HIF-1α, was greatly inhibited in the cirrhotic livers by celecoxib. HIF-1α is generally considered as one of the potential transcription factor-binding sites for VEGF. p-ERK is considered as essential inducer for VEGF receptor expression [28]. Up-regulation of p-ERK- c-fos pathway by COX-2 activation was observed in TAA group. Co-treatment with celecoxib led to down-regulation of p-ERK/c-fos pathway which could at least partly explain its inhibitory effect on VEGFR-2 expression.

Portal hypertension, a major complication of liver cirrhosis, can cause lethal complications, such as gastrointestinal variceal hemorrhage, ascites, hepatorenal syndrome and hepatic encephalopathy [1]. Historically treatment of portal hypertension has been mainly focusing on the complications. Currently, more attention has been paid to the intrahepatic anti-angiogenes is because portal hypertension is initiated in large part through increases of intrahepatic vascular resistance. However, few agents with a potential to reduce intrahepatic neovasculature have been used in the treatment of portal hypertension. On the basis of excluding the discrepancy of heart output among three groups, the present study verified the protective effect of celecoxib on the portal pressure in the TAA-treated rats. Furthermore, the morphological evidence of portal venules in three-dimension displayed by vascular casts among three groups provided an important tool to evaluate the relationship between portal hypertension and liver angiogenesis. Compared with the intuitively normal architecture of portal venules TAA treatment resulted in a tortuous vascular network of varying diameter and flow pattern, which were organized into micronodules and macronodules in the cirrhotic liver. Such profound changes clearly increased the inflow resistance and enhanced portal pressure about 60% in the rats treated with TAA. With the addition of celecoxib, the portal hypertension was significantly decreased most likely due to the amelioration of intrahepatic angiogenesis and fibrosis.

In contrast to the results in this study, some studies arguing against the effects of celecoxib on anti-fibrosis have been reported [29,30]. The experiment term of cirrhotic model used in Yu’s group was quite shorter than that in our study, 2 weeks vs. 16 weeks of TAA treatment. Thus the data provided from Yu’s group, such as ALT, tumour necrosis factor-α, interleukin (IL)-1β and IL-6, mainly reflect a sub-acute inflammation other than typical chronic one. Differently, they did not examine the intrahepatic angiogenesis as one of the outcomes. In their study, the hepatic expression of COX-2 was not observed and its downstream eicosanoids was not inhibited by celecoxib treatment. The discrepancies between these two studies may suggest the better protective efficacy of celecoxib in the development of liver cirrhosis could be achieved in the setting of the chronic term with an extended treatment of TAA. Another study reported a detrimental role of celecoxib by showing that celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum [31], which may suggest that the effect of celecoxib in the prevention of liver cirrhosis might be dependent on the etiological differences of animal models.

Celecoxib has been widely used in the clinical treatment of osteoarthritis and rheumatoid arthritis [32]. A review of controlled clinical trials involving 6376 patients suggests that celecoxib has a very low risk for hepatotoxicity, even after exposures of as long as 2 years at therapeutic doses [33]. In this study, the biochemical parameters including liver and renal tests were comparable in three groups (Table 2), indicating that the long term use of celecoxib did not exacerbate hepatic and renal injuries in this model. Our results suggest that celecoxib is safe and efficacious in the prevention of liver cirrhosis in this animal model.

Celecoxib Ameliorates Portal Hypertension

Figure 5. Decrease of portal hypertension by celecoxib treatment. There were no significant differences of the mean arterial pressure and heart rate among three groups, p > 0.05. The portal pressure measured by introduced catheters in TAA group was the highest among three groups. # p < 0.01 vs. control group; * p < 0.01 vs. TAA group. doi:10.1371/journal.pone.0069309.g005

resulted in a tortuous vascular network of varying diameter and flow pattern, which were organized into micronodules and macronodules in the cirrhotic liver. Such profound changes clearly increased the inflow resistance and enhanced portal pressure about 60% in the rats treated with TAA. With the addition of celecoxib, the portal hypertension was significantly decreased most likely due to the amelioration of intrahepatic angiogenesis and fibrosis.

In contrast to the results in this study, some studies arguing against the effects of celecoxib on anti-fibrosis have been reported [29,30]. The experiment term of cirrhotic model used in Yu's group was quite shorter than that in our study, 2 weeks vs. 16 weeks of TAA treatment. Thus the data provided from Yu's group, such as ALT, tumour necrosis factor-α, interleukin (IL)-1β and IL-6, mainly reflect a sub-acute inflammation other than typical chronic one. Differently, they did not examine the intrahepatic angiogenesis as one of the outcomes. In their study, the hepatic expression of COX-2 was not observed and its downstream eicosanoids was not inhibited by celecoxib treatment. The discrepancies between these two studies may suggest the better protective efficacy of celecoxib in the development of liver cirrhosis could be achieved in the setting of the chronic term with an extended treatment of TAA. Another study reported a detrimental role of celecoxib by showing that celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum [31], which may suggest that the effect of celecoxib in the prevention of liver cirrhosis might be dependent on the etiological differences of animal models.
might be considered as a potential agent in the preventive strategy of liver cirrhosis for the patients with chronic hepatic diseases.

Acknowledgments

The authors would like to thank associate professor Rui Liu, technicians Xian Li and Ou Qiang from Division of Peptides Related with Human Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Shu-Ping Zheng from Analytical and Testing Center, Sichuan University, for their technical assistance.

Author Contributions

Conceived and designed the experiments: CWT. Performed the experiments: JHG SLW WJY YYL. Analyzed the data: HT ZYH. Contributed reagents/materials/analysis tools: HT ZYH. Wrote the paper: JHG ZXL CWT.

References

1. Bosch J, Garcia-Pagan JC (2000) Complications of cirrhosis. I. Portal hypertension. J Hepatol 32: 141–156.
2. Bosch J, Abraides JG, Fernandez M, Garcia-Pagan JC (2010) Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53: 558–567.
3. Thabut D, Shah V (2010) Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 53: 976–980.
4. Taura K, De Minicis S, Seki E, Hatano E, Iwaiako K, et al. (2006) Hepatic stellate cells secrete angioptins-1 that induces angiogenesis in liver fibrosis. Gastroenterology 135: 1729–1738.
5. Corpechot C, Barbu V, Wendum D, Kimmann N, Rey C, et al. (2002) Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35: 1010–1021.
6. Masuy TK, Ritman EL, La Russa NF (2003) Hepatic artery and portal vein remodeling in rat liver: vascular response to selective cholangiocyte proliferation. Am J Pathol 162: 1173–1182.
7. Jain RK, Carmeliet P (2012) SnapShot: Tumor angiogenesis. Cell 149: 1408–1408 e1-401.
8. Tugus S, Fernandez-Varo G, Munoz-Luque J, Ron J, Arroyo V, et al. (2007) Antiangiogenic treatment with sulfatin mabelelates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46: 1919–1926.
9. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, et al. (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54: 373–373.
10. Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, et al. (2011) Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 53: 1629–1640.
11. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298–307.
12. Samant RS, Shvede LA (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2: 122–134.
13. Verheul HM, Pinedo HM (2010) Complications of cirrhosis. II. Portal hypertension. J Hepatol 53: 558–567.
14. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Cancer 9: 445–453.
15. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145–182.
16. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, et al. (2009) Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci 1155: 293–299.
17. Sahin M, Sahin E, Gumuslu S (2009) Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60: 242–253.
18. Xie Y, Chen S, Wang CH, Tang CW (2011) SOM230 combined with celecoxib prolongs the survival in nude mice with HepG2-xenografts. Cancer Biol Ther 12: 86–92.
19. Tong H, Li X, Zhang CL, Gao JH, Wen SL, et al. (2013) Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. J Dig Dis 14: 29–37.
20. Wang R, Guo L, Wang P, Yang W, Lu Y, et al. (2013) Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des 19: 115–125.
21. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655–1669.
22. Fallowfield JA (2011) Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300: G709–715.
23. Rockey DC (2008) Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12: 939–962, xi.
24. Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, et al. (2009) Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 59: 1517–1527.
25. Lee JS, Semela D, Iredale J, Shah VH (2007) Sinusoidal remodeling and angiogenesis: a new function for the liver-specific periostin? Hepatology 45: 817–825.
26. Mejias M, Garcia-Pras E, Tiana C, Miquel R, Bosch J, et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49: 1245–1256.
27. Patonsek E, Popov Y, Stickel F, Schneider V, Ledermann M, et al. (2009) Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50: 1501–1511.
28. Xiao Z, Kong Y, Yang S, Li M, Wen J, et al. (2007) Upregulation of Hk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. Cell Res 17: 73–79.
29. Hui AV, Leung WK, Chan HL, Chan FK, Go MY, et al. (2006) Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 26: 125–136.
30. Yu J, Hui AV, Chiu ES, Go MY, Cheung KD, et al. (2009) The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile-duct-ligated rats. Liver Int 29: 25–36.
31. Liu H, Wei W, Li X (2009) Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. Prostaglandin Lipid Mediat 88: 63–67.
32. McCormack PL (2011) Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71: 2457–2489.
33. Maddovy WC, Maurath C, Verburg KM, Geis GS (2000) The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Ann J Thor 7: 153–158.